According to Zhitong Finance App News, Aoxiang Pharmaceutical (603229.SH) disclosed its 2026 third quarter report. The company achieved revenue of 610 million yuan in the first three quarters, a year-on-year decrease of 5.53%; net profit to mother of 71.9313 million yuan, a year-on-year decrease of 65.26%; deducted non-net profit of 56,1982 million yuan, a year-on-year decrease of 69.33%; basic earnings per share were 0.09 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.